Dendritic cells lentivirally engineered to overexpress interleukin-10 inhibit contact hypersensitivity responses, despite their partial activation induced by transduction-associated physical stress

Journal of Gene Medicine

Volumn 12, Issue 3, 2010, Pages 231-243

  Besche, Verena ^a   Wiechmann, Nadine ^a   Castor, Timo ^a   Trojandt, Stefanie ^a   Höhn, Yvonne ^a   Kunkel, Hanna ^b   Grez, Manuel ^b   Grabbe, Stephan ^a   Reske Kunz, Angelika B ^a   Bros, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Institute for Biomedical Research   (Germany)

Author keywords

Contact hypersensitivity; Fascin promoter; Gene therapy; Lentiviral transduction; Murine dendritic cells

Indexed keywords

ALPHA2 INTERFERON; BETA1 INTERFERON; CHEMOKINE RECEPTOR CCR7; HAPTEN; INTERLEUKIN 10; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MATURATION; CELL STRAIN HEK293; CONTACT SENSITIVITY; CONTACT SENSITIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENE OVEREXPRESSION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSICAL STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; DENDRITIC CELLS; DERMATITIS, ALLERGIC CONTACT; FEMALE; GENETIC ENGINEERING; IMMUNOTHERAPY; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; STRESS, PHYSIOLOGICAL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

MURINAE; MUS;

EID: 77349104355     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1436     Document Type: Article

References (35)

1. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9: 239-244.
2. Adams S, O'Neill DW, Bhardwaj N. Recent advances in dendritic cell biology. J Clin Immunol 2005; 25: 87-98.
3. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007; 14: 847-862.
4. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-80.
5. Ross R, Sudowe S, Beisner J, et al. Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin. Gene Ther 2003; 10: 1035-1040.
6. Kikuchi T. Genetically modified dendritic cells for therapeutic immunity. Tohoku J Exp Med 2006; 208: 1-8.
7. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004; 6: 1175-1188.
8. Bros M, Wiechmann N, Besche V, Castor T, Sudowe S, Reske-Kunz AB. A plasmid DNA elec-troporation method allows transfection of murine DC. J Immunol Meth 2009; 343: 13-20.
9. Breckpot K, Emeagi P, Dullaers M, Michiels A, Heirman C, Thielemans K. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther 2007; 18: 536-546.
10. Breckpot K, Dullaers M, Bonehill A, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003; 5: 654-667.
11. He Y, Zhang J, Mi Z, Robbins P, Falo LD. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005; 174: 3808-3817.
12. Fresnay S, Chalmers DE, Ferrand C, et al. Polybrene and interleukin-4: two opposing factors for retroviral transduction of bone-marrow-derived dendritic cells. J Gene Med 2002; 4: 601-612.
13. Feili-Hariri M, Falkner DH, Morel PA. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-drivenmurine dendritic cell populations: implications for immunotherapy. J Leukoc Biol 2005; 78: 656-664.
14. Maroof A, Penny M, Kingston R, et al. Interleukin-4 can induce interleukin-4 production in dendritic cells. Immunology 2006; 117: 271-279.
15. -) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996; 62: 659-665.
16. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255.
17. Scheicher C, Mehlig M, Zecher R, Reske K. Dendritic cells from mouse bone marrow: in vitro differentiation using low doses of recombinant granulocyte-macrophage colony-stimulating factor. J Immunol Meth 1992; 154: 253-264.
18. Gisch K, Gehrke N, Bros M, et al. Formalin-fixed Staphylococcus aureus particles prevent allergic sensitization in a murine model of type I allergy. Int Arch Allergy Immunol 2007; 144: 183-196.
19. ZalT, VolkmannA, StockingerB. Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 1994; 180: 2089-2099.
20. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
21. FollenziA, SabatinoG, LombardoA, BoccaccioC, NaldiniL. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-260.
22. Bros M, Jährling F, Renzing A, et al. A newly established murine immature dendritic cell line can be differentiated into a mature state, but exerts tolerogenic function upon maturation in the presence of glucocorticoid. Blood 2007; 109: 3820-3829.
23. Weigmann B, Jarman ER, Sudowe S, Bros M, Knop J, Reske-Kunz AB. Induction of regulatory T cells by leflunomide in a murine model of contact allergen sensitivity. J Invest Dermatol 2006; 126: 1524-33.
24. Ross R, Ross XL, Schwing J, Längin T, Reske-Kunz AB. The actin-bundling protein fascin is involved in the formation of dendritic processes in maturing epidermal Langerhans cells. J Immunol 1998; 160: 3776-3782.
25. Ross R, Jonuleit H, Bros M, et al. Expression of the actin-bundling protein fascin in cultured human dendritic cells correlates with dendritic morphology and cell differentiation. J Invest Dermatol 2000; 115: 658-663.
26. Janmey PA, McCulloch CA. Cell mechanics: integrating cell responses to mechanical stimuli. Annu Rev Biomed Eng 2007; 9: 1-34.
27. Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005; 105: 3824-3832.
28. Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC. Fascins, and their roles in cell structure and function. BioEssays 2002; 24: 350-361.
29. Sudowe S, Ludwig-Portugall I, Montermann E, Ross R, Reske-Kunz AB. Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. Mol Ther 2003; 8: 567-575.
30. Shearwin KE, Callen BP, Egan JB. Transcriptional interference - a crash course. Trends Genet 2005; 21: 338-345.
31. Morita A, Ariizumi K, Ritter R, et al. Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter. Gene Ther 2001; 8: 1729-1737.
32. + anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99: 2468-2476.
33. Smits HH, de Jong EC, Wierenga EA, Kapsenberg ML. Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 2005; 26: 123-129.
34. Takayama T, Tahara H, Thomson AW. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth. Transplantation 2001; 71: 1334-1340.
35. Dai R, Streilein JW. Ultraviolet B-exposed and soluble factor pre-incubated epidermal Langerhans cells fail to induce contact hypersensitivity and promote DNP-specific tolerance. J Invest Dermatol 1997; 108: 721-726.